In APOE ε4 non-carriers, PVRL2 rs6859 still had a significant association with MCI-AD progression adjusting for age and gender (AG/AA vs. GG, HR (95% CI) = 2.23 (1.07–4.65), p = .032); however, PVRL2 rs6859 and APOE had no interactive effect on MCI-AD progression (Pinter rs6859×APOE = 0.567) (Supplementary Table S2). This evidence concerns the gene APOE and Alzheimer disease.